FDA De Novo listing places Better Therapeutics’ BT-001 in the novel-device pathway
The FDA’s De Novo database lists BT-001 from Better Therapeutics with a decision date of 07/07/2023. The entry appears on the agency’s De Novo classification page, the regulatory track reserved for medical devices that do not fit an existing predicate classification and therefore require a new pathway rather than a conventional 510(k) clearance. In practical terms, the listing means the device has been assigned a formal place within FDA’s device taxonomy, even though the database excerpt provides no indication-specific narrative, clinical summary, or performance details.
One line in a regulatory database can change how a device enters the market.
What the De Novo record does, and does not, say
The database entry identifies BT-001 by device name, links it to Better Therapeutics, and provides the De Novo number DEN220058. No 510(k) number appears alongside the listing, which is consistent with the De Novo route. The page also sits within a broader catalog of other FDA device decisions, indicates that this is a classification record rather than a full clinical review article. For clinicians and medical-device watchers, the key fact is not the volume of surrounding entries but the assignment of BT-001 to a defined regulatory category on a specific date.
A De Novo decision does not, by itself, tell a clinician what the device treats, how it is used, or what endpoints supported review. Those details are absent here, and they should not be inferred from the listing alone. The FDA record is administrative in nature, but administrative designation matters because it shapes the next stage of evidence generation, labeling, market access, and downstream adoption. When a device lands in De Novo, the agency is acknowledging novelty rather than incremental modification.
Why the De Novo pathway matters in device regulation
The De Novo mechanism was created for low- to moderate-risk devices that lack a legally marketed predicate. That distinction is central because it separates genuinely new technologies from products that can be reviewed by comparison to prior devices. For clinicians, the pathway can signal that a product may represent a new clinical tool, a new software function, or a new delivery model that does not cleanly map onto older device categories. For regulators, it establishes controls that can support future 510(k) submissions for similar devices.
In the absence of product-specific trial data on this page, the most defensible interpretation is limited to classification. The record confirms that BT-001 passed through the De Novo process and received a dated decision in mid-2023. It does not reveal whether the device is software-based, hardware-based, adjunctive, or disease-specific. It also does not provide adverse-event data, comparative effectiveness results, or patient-selection guidance. Those omissions are not minor; they define the boundaries of what can be said responsibly from the available material.
The clinical significance of a sparse regulatory entry
A sparse database entry can still be clinically consequential. Regulatory classification is often the gate through which a novel device must pass before it reaches routine use, and the date attached to that classification helps anchor the timeline for reimbursement discussions, health-system evaluation, and postmarket monitoring. Once a device enters the De Novo category, subsequent investigators and manufacturers may use that classification as a reference point when developing related technologies.
For bedside decision-making, however, this record is not enough to support use recommendations. There is no indication in the available text of intended population, contraindications, or comparative benefit over standard care. There is also no device description that would allow a clinician to map BT-001 to a specific organ system or disease state. In a medical newsroom, restraint is essential: a regulatory entry is real, but its clinical meaning remains narrow until paired with the underlying submission and supporting evidence.
What can be said with confidence from the FDA page
The FDA listing establishes four concrete facts. BT-001 is associated with Better Therapeutics. The device carries De Novo number DEN220058. The decision date is 07/07/2023. And the record appears within the FDA’s Device Classification Under Section 513(f)(2) (De Novo) database, indicating a novel-device classification rather than a predicate-based clearance.
That is the extent of the verified record. Everything beyond it—mechanism, target condition, patient selection, clinical performance, and adoption potential—would require additional source material and cannot be reconstructed from the page alone. For readers tracking medical-device regulation, the entry is still useful because it marks the point at which a novel product became formally classifiable by the agency. For clinicians, the more important unanswered question is not whether the record exists, but what evidence accompanies it outside this index page.